Encompass Health (NYSE:EHC) Releases Earnings Results, Beats Expectations By $0.19 EPS

Encompass Health (NYSE:EHC) announced its quarterly earnings results on Wednesday. The company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.93 by $0.19, Briefing.com reports. Encompass Health had a return on equity of 17.69% and a net margin of 7.33%. The business had revenue of $1.32 billion for the quarter, compared to analyst estimates of $1.27 billion. During the same quarter in the previous year, the company earned $0.88 EPS. The company’s quarterly revenue was up 13.4% on a year-over-year basis. Encompass Health updated its FY24 guidance to $3.86-4.11 EPS.

Encompass Health Trading Down 0.5 %

Encompass Health stock traded down $0.43 during trading on Thursday, reaching $82.37. The company had a trading volume of 445,694 shares, compared to its average volume of 659,084. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.28 and a current ratio of 1.28. The firm has a market capitalization of $8.25 billion, a price-to-earnings ratio of 23.57, a PEG ratio of 1.53 and a beta of 0.94. Encompass Health has a 12-month low of $57.55 and a 12-month high of $85.84. The stock’s 50 day moving average price is $77.89 and its two-hundred day moving average price is $70.67.

Encompass Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Monday, April 1st were paid a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.73%. The ex-dividend date was Thursday, March 28th. Encompass Health’s dividend payout ratio is currently 17.29%.

Analyst Ratings Changes

Several analysts have weighed in on the company. Mizuho upped their target price on Encompass Health from $93.00 to $95.00 and gave the company a “buy” rating in a report on Thursday. Truist Financial raised their target price on shares of Encompass Health from $82.00 to $86.00 and gave the company a “buy” rating in a report on Friday, February 9th. Barclays upped their price target on shares of Encompass Health from $95.00 to $101.00 and gave the company an “overweight” rating in a report on Thursday, March 28th. Royal Bank of Canada reissued an “outperform” rating and set a $83.00 price objective on shares of Encompass Health in a research note on Friday, February 9th. Finally, Stephens reissued an “overweight” rating and set a $85.00 price target on shares of Encompass Health in a research report on Tuesday, January 16th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $84.67.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.